HUDSON
BIOTECH
OUR PEPTIDES
Pure Peptides, Trusted Quality
Hudson Biotech provides premium peptide solutions for research, wellness, and advanced scientific applications, delivering high-quality formulations with a focus on innovation, performance, and reliable sourcing.
Peptide Portfolio
Explore our peptide portfolio. Each program is supported by custom synthesis, analytical characterization, and documentation aligned with research and clinical-trial requirements.
Retatrutide (LY3437943)
Triple Hormone Receptor Agonist | GIP / GLP-1 / Glucagon
Key Identifier: NCT07467447
Key Identifier:
NCT07467447
Primary Area:
Obesity / metabolic disease
Status:
Investigational – not FDA approved
FDA Note:
Not approved for any indication and not permitted for compounding under federal law
Tirzepatide
Tirzepatide is identified in FDA labeling as a dual GIP and GLP-1 receptor agonist. Public registry sources reference a Phase 3 study (NCT07481747) evaluating its use in adults with obesity or overweight without type 2 diabetes.
Key Identifier:
NCT07481747
Primary Area:
Obesity / type 2 diabetes / weight management
Status:
Approved for specific indications; investigational for other uses
FDA Note:
Approved as Mounjaro and Zepbound for labeled indications only
BPC 157
BPC-157 is a 15-amino-acid investigational peptide listed in the FDA UNII database. Publicly available records reference a Phase 2 clinical study (NCT07437547) evaluating its use in acute grade II hamstring strain.
Key Identifier:
NCT07437547
Primary Area:
Soft tissue repair / sports medicine
Status:
Investigational – not FDA approved
FDA Note:
Not part of any FDA-approved drug; not on the 503A bulks list
Tesamorelin
Tesamorelin is an FDA-approved GHRH analog used for HIV-associated lipodystrophy. Investigational research is also exploring its potential role in reducing liver fat accumulation (NCT07481734).
Key Identifier:
NCT07481734
Primary Area:
HIV lipodystrophy / liver fat
Status:
Approved for limited use; investigational beyond labeled indications
FDA Note:
Not indicated for weight management
GHK-Cu (Copper Tripeptide-1)
Copper-Peptide Complex
GHK-Cu is an investigational peptide complex studied in wound healing. Public data reference a Phase 2 study (NCT07437586).
Key Identifier:
NCT07437586
Primary Area:
Wound healing / dermatology
Status:
Investigational – not FDA approved
FDA Note:
Potential risks include immunogenicity and peptide-related impurities
TB-500
Thymosin Beta-4 Fragment (17–23)
TB-500 is a peptide fragment associated with tissue repair research and cardiovascular applications.
Key Identifier:
NCT07487363
Primary Area:
Cardiovascular / tissue repair
Status:
Investigational – not FDA approved
FDA Note:
Listed by WADA as a prohibited substance in sport
Melanotan II
Synthetic Cyclic Heptapeptide | Alpha-Melanotropin Analog.
Melanotan II is a cyclic peptide studied for pigmentation-related applications, including vitiligo.
Key Identifier:
NCT07437560
Primary Area:
Pigmentation / melanocortin pathway
Status:
Investigational – not FDA approved
FDA Note:
Classified as an unapproved new drug with safety concerns
Custom Peptide Synthesis Support
Hudson Biotech provides custom peptide synthesis tailored to research and clinical-trial programs, with support across characterization, quality planning, and batch documentation needs.
01 Sequence confirmation and identity testing
Supports confirmation of peptide identity using appropriate analytical methods and documentation aligned with program requirements.
02 Phase-appropriate purification
Purification planning can be aligned with the intended development stage, material use case, and expected quality profile.
03 Impurity profiling and control
Impurity review helps teams understand peptide-related impurities, process-related concerns, and control expectations.
04 Stability planning and documentation
Stability planning may support storage, handling, shipping, and study-readiness discussions for peptide material.
05 Batch release and certificate of analysis
Batch documentation may include release information, certificate of analysis, traceability details, and quality-review support.
Quality & Documentation
Clinical Documentation Stack
Robust documentation is critical for clinical research and supports quality control, study credibility, regulatory readiness, and reliable interpretation of investigational material performance.
01 Sequence-level identity confirmation
Confirms that the peptide identity aligns with the expected sequence, naming convention, and material specification.
02 Phase-appropriate purity specifications
Supports quality expectations that match the intended research stage, clinical phase, or development program requirement.
03 Impurity characterization and control
Helps identify, track, and manage peptide-related or process-related impurities across the material lifecycle.
04 Stability data for handling and storage
Supports decisions around storage conditions, temperature control, shipment planning, and study-use timelines.
05 Batch release documentation
Provides batch-level traceability, quality review, certificate of analysis support, and release-readiness information.
06 CMC support for regulatory submissions
Supports chemistry, manufacturing, and controls documentation needed for structured regulatory or clinical-program review.
Compliance Information
Investigational:
All peptides are investigational unless stated otherwise.
Research Use:
Intended solely for qualified research and clinical-trial applications.
ClinicalTrials.gov References:
Some entries may be mock or example records. Verify directly with official sources.